Clinical study of navigation surgery for hepatoblastoma using Indocyanine Green (ICG)

Clinical study of navigation surgery for hepatoblastoma using Indocyanine Green (ICG) - Clinical study of navigation surgery for hepatoblastoma using Indocyanine Green (ICG)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026474

Enrollment

Registered

2017-03-10

Start date

2017-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatoblastoma

Interventions

Intravenous injection of ICG 0.5mg/kg, 24-72 hours before the operation. Visualization of lesions taking up ICG by a fluorescent camera at the time of operation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients suspected with primary or metastatic hepatoblastoma

Exclusion criteria

Exclusion criteria: Ones who are allergic to ICG or Iodine or who are ineligible for surgery are excluded.

Design outcomes

Primary

Measure	Time frame
Pathological accuracy of the specimens that are positive for ICG	—

Secondary

Measure	Time frame
To prove the non-inferiority of ICG navigation surgery compared with current available image modalities, and survival proportions in 1,3,5 years after the surgery.	—

Countries

Japan

Contacts

Public ContactTeizaburo Mori

Keio University School of Medicine The department of pediatric surgery

0105mori@keio.jp+81-3-5363-3024

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026